Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in relapsed or refractory gastric cancer
NCT00568529Phase 2Suspended
- Sponsor
- Fudan University
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in gastric cancer (GC), sponsored by Fudan University. Started Oct 2007; status: suspended.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00568529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568529.